IncellDx Signs Agreement With Bristol-Myers Squibb Related to the Development
of an Assay for a Companion Diagnostic Test
MENLO PARK, Calif., Oct. 29, 2013 (GLOBE NEWSWIRE) -- IncellDx, Inc. announced
today that they have entered into an agreement with Bristol-Myers Squibb
Company (NYSE:BMY) related to the development of an assay for potential
application in a molecular companion diagnostic intended to identify patients
likely to benefit from treatment with a Bristol-Myers Squibb drug that is
currently under development.
The test will be based upon a modification of IncellDx's quantitative
InCellCept assay, a cell-based instrument capable of quantifying molecular
biomarkers inside intact cells. This allows protein and gene expression to be
measured by distinct cell type, which aids both diagnosis and disease
localization. If successful, the companies anticipate extending the
relationship into development of a molecular companion diagnostic in which the
assay would be used to determine phenotypic susceptibility of patients'
disease prior to treatment.
This collaboration with Bristol-Myers Squibb highlights IncellDx's commitment
to precision diagnostics and personalized medicine. "The agreement highlights
the breadth of IncellDx's novel cellular multiplexing molecular technology,"
commented Bruce Patterson, MD, CEO of IncellDx.
Financial terms of the agreement were not disclosed.
About IncellDx Inc.
IncellDx, Inc. is a molecular diagnostics company dedicated to the detection
and monitoring of life threatening diseases such as cervical cancer, breast
cancer, HIV/AIDs, hepatitis, and organ transplant rejection. For more
information, please visit www.incelldx.com.
CONTACT: Eric Hass
Press spacebar to pause and continue. Press esc to stop.